Diagnostic Products Corporation Announces Quarterly Dividend

As previously announced, Diagnostic Products Corporation enteredinto a merger agreement under which Siemens Medical Solutions USA, awholly owned subsidiary of Siemens AG (NYSE:SI), would acquire DPCfor approximately $1.86 billion.

Siemens Medical Solutions, with headquarters in Malvern,Pennsylvania, and Erlangen, Germany, is one of the largest suppliersto the healthcare industry in the world. The company is known forbringing together innovative medical technologies, healthcareinformation systems, management consulting, and support services, tohelp customers achieve tangible, sustainable, clinical and financialoutcomes. Employing approximately 33,000 people worldwide andoperating in more than 120 countries, Siemens Medical Solutionsreported sales of EUR 7.6 billion, orders of EUR 8.6 billion and groupprofit of EUR 976 million for fiscal 2005 (September 30). Moreinformation can be obtained by visitingwww.usa.siemens.com/medical-pressroom.

Diagnostic Products Corporation, founded in 1971, is a leader inthe global in vitro diagnostics market. DPC's product offeringincludes the widely accepted IMMULITE(R) series of immunoassaysystems, more than 75 immunoassays and an expanding menu of essentialspecific allergens and allergy panels that are run just like otherimmunoassays. DPC also designs and manufactures automated laboratoryinstrumentation and automation solutions that provide fast, accurateresults while enabling our customers to do "more with less" in aleaner laboratory. DPC's combined chemistry and immunoassay menu isone of the largest and most diversified available, covering mostlaboratory tests requested. In fiscal 2005 (December 31), DPC reportedsales of $481 million and income from operations of $96 million.Additional information can be found on DPC's website atwww.dpcweb.com.

DPC has filed proxy materials regarding the proposed mergerdescribed in this communication with the Securities and ExchangeCommission. Investors and security holders are urged to read the proxystatement, because it will contain important information about DPC andthe proposed merger. A definitive proxy statement has been sent tosecurity holders of DPC seeking their approval of the transaction.Investors and security holders may obtain a free copy of thedefinitive proxy statement and other documents filed by DPC with theSEC at the SEC's website at www.sec.gov. The definitive proxystatement and other relevant documents may also be obtained free ofcost by directing a request to DPC, 5210 Pacific Concourse Drive, LosAngeles, California 90045, attention: Investor Relations (telephone310-645-8200).

DPC and its directors and executive officers may be deemed to beparticipants in the solicitation of proxies from the shareholders ofDPC in connection with the merger. Information about DPC and itsdirectors and executive officers can be found in DPC's ProxyStatements and Annual Reports on Form 10-K filed with the SEC.Additional information regarding the interests of those persons may beobtained by reading the proxy statement.

Except for the historical information contained herein, this pressrelease contains forward-looking statements that involve risks anduncertainties that could cause actual results to differ materially.These factors include governmental or other action relating to DPC'sChinese affiliate; the rate of customer demand for DPC's products;DPC's ability to successfully market new and existing products; itsdependence on certain suppliers; domestic and foreign governmentregulation; its ability to keep abreast of technological innovationsand to translate them into new products; competition; political andeconomic instability in certain markets including the movements offoreign currencies relative to the dollar; and other risks anduncertainties disclosed from time to time in DPC's SEC reports andfilings.